{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=26", "query": { "condition": "Multiple Myeloma", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 2318, "total_pages": 232, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=27&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=25&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T02:29:09.761Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04017130", "title": "A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed and/or Refractory Multiple Myeloma" ], "interventions": [ { "name": "MT-0169", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Molecular Templates, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2020-02-05", "completion_date": "2023-12-13", "has_results": false, "last_update_posted_date": "2024-01-17", "last_synced_at": "2026-10-27T02:29:09.761Z", "location_count": 7, "location_summary": "Los Angeles, California • Jacksonville, Florida • Miami, Florida + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04017130" }, { "nct_id": "NCT00772915", "title": "Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "dexamethasone", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 39, "start_date": "2008-12-03", "completion_date": "2018-06-27", "has_results": true, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-10-27T02:29:09.761Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00772915" }, { "nct_id": "NCT01947140", "title": "Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoid Malignancies", "Multiple Myeloma", "Lymphoma", "Hodgkin Lymphoma", "Non-hodgkin Lymphoma" ], "interventions": [ { "name": "Pralatrexate", "type": "DRUG" }, { "name": "Romidepsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jennifer Amengual", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2013-09-09", "completion_date": "2022-09-01", "has_results": true, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-27T02:29:09.761Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01947140" }, { "nct_id": "NCT00531284", "title": "Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Renal Cancer", "Non-small Cell Lung Cancer", "Small Cell Lung Cancer", "Solid Tumors", "Multiple Myeloma", "Lymphoma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 184, "start_date": "2007-09", "completion_date": "2017-05-22", "has_results": true, "last_update_posted_date": "2017-08-15", "last_synced_at": "2026-10-27T02:29:09.761Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Beverly Hills, California • Chicago, Illinois + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00531284" }, { "nct_id": "NCT00898235", "title": "Collection of Samples and Clinical Data From Patients With Amyloid Diseases", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "clonality analysis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "protein analysis", "type": "GENETIC" }, { "name": "biologic sample preservation procedure", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "fluorescence spectroscopy", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Boston Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10000, "start_date": "2000-01", "completion_date": "2040-12", "has_results": false, "last_update_posted_date": "2025-12-01", "last_synced_at": "2026-10-27T02:29:09.761Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00898235" }, { "nct_id": "NCT05000450", "title": "Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Multiple Myeloma" ], "interventions": [ { "name": "ALLO-605", "type": "GENETIC" }, { "name": "ALLO-647", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "BIOLOGICAL", "DRUG" ], "sponsor": "Allogene Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-06-06", "completion_date": "2023-10-11", "has_results": false, "last_update_posted_date": "2024-06-28", "last_synced_at": "2026-10-27T02:29:09.761Z", "location_count": 4, "location_summary": "Denver, Colorado • Austin, Texas • Houston, Texas + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Austin", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05000450" }, { "nct_id": "NCT02230917", "title": "A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Sotatercept", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rebecca Silbermann", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-10", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2016-09-01", "last_synced_at": "2026-10-27T02:29:09.761Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02230917" }, { "nct_id": "NCT03702725", "title": "Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Multiple Myeloma", "Multiple Myeloma in Relapse", "Multiple Myeloma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance Foundation Trials, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2019-08-29", "completion_date": "2024-10-04", "has_results": true, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-10-27T02:29:09.761Z", "location_count": 5, "location_summary": "Maywood, Illinois • Boston, Massachusetts • Winston-Salem, North Carolina + 2 more", "locations": [ { "city": "Maywood", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT03702725" }, { "nct_id": "NCT00609817", "title": "Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "GCS-100", "type": "DRUG" }, { "name": "Bortezomib/Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "La Jolla Pharmaceutical Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2008-05", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2013-06-25", "last_synced_at": "2026-10-27T02:29:09.761Z", "location_count": 3, "location_summary": "Gainesville, Florida • Boston, Massachusetts • Milwaukee, Wisconsin", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00609817" }, { "nct_id": "NCT01416428", "title": "Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "oprozomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2011-10-15", "completion_date": "2019-08-12", "has_results": false, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-10-27T02:29:09.761Z", "location_count": 19, "location_summary": "Scottsdale, Arizona • Salinas, California • Denver, Colorado + 14 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Salinas", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01416428" } ] }